http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1327870-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a09fa84c54c24536575f7f12c1f1db43 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-542 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-552 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2720-10034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5254 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 |
| filingDate | 1971-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1973-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1327870-A |
| titleOfInvention | Process for the manufacture of a vaccine against infectious bursitis of chickens |
| abstract | 1327870 Attenuated infective bursitis virus and vaccine thereof BEHRINGWERKE AG 13 Sept 1971 [12 Sept 1970] 42552/71 Heading A5B An attenuated infective bursitis virus, or a vaccine comprising such virus, is prepared by infecting one or more mice with infective virus, and attenuating the virus by serial passages in mice and extracting the attenuated virus so obtained, and, if desired, preparing a vaccine therefrom in known manner. The mice may be treated with an immuno-suppressive agent, preferably by subcutaneous injection, after infection of the mouse with the bursitis virus, in an amount of from 50 to 500γ of the agent per mouse. The immuno-suppressive agent may be a corticosteroid such as cortisone, hydrocortisone, prednisone, prednisolone, 6-methyl-prednisolone, dexamethasone or paramethasone and their physiologically tolerable esters; or an anti-metabolite e.g. 6-mercaptopurine; an alkylating agent e.g. cyclophosphamide; and antilymphocytic serum or antilymphocytic globulin. The mouse may be a baby mouse having an age of 1 to 3 days preferably of the white mouse or Mastomys natalensis species, and may be infected with a suspension isolated from the Bursa fabricii of a bird infected with bursitis from 18 to 25 serial passages in mice may be effected and the immuno-suppressive agent is not used until after 10, 11 or 12 passages in mice. The attenuation process may also comprise 1 or more passages in chicken eggs, preferably effected before the serial passages in mice. The attenuated virus or vaccine, which may comprise the viral suspension containing a protective colloid, may be lyophilized. Commercially reared birds are immunized against infective bursitis by administration thereto, preferably by means of the drinking water, of the attenuated virus or vaccine prepared therefrom. |
| priorityDate | 1970-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.